sitagliptin/metformin "krka" 50+1000 mg filmovertrukne tabletter
krka d.d. novo mesto - metforminhydrochlorid, sitagliptin - filmovertrukne tabletter - 50+1000 mg
sitagliptin/metformin "sandoz" 50+1000 mg filmovertrukne tabletter
sandoz a/s - metforminhydrochlorid, sitagliptinhydrochlorid - filmovertrukne tabletter - 50+1000 mg
vildagliptin/metformin "tiefenbacher" 50+850 mg filmovertrukne tabletter
alfred e. tiefenbacher gmbh & co. kg - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+850 mg
vildagliptin/metformin "stada" 50+850 mg filmovertrukne tabletter
stada arzneimittel ag - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+850 mg
metformin "laurus" 500 mg filmovertrukne tabletter
laurus generics gmbh - metforminhydrochlorid - filmovertrukne tabletter - 500 mg
metformin "teva b.v." 850 mg filmovertrukne tabletter
teva b.v. - metforminhydrochlorid - filmovertrukne tabletter - 850 mg
metformin "actavis" 850 mg filmovertrukne tabletter
actavis group ptc ehf. - metforminhydrochlorid - filmovertrukne tabletter - 850 mg
metformin "vitabalans" 500 mg filmovertrukne tabletter
vitabalans oy - metforminhydrochlorid - filmovertrukne tabletter - 500 mg
metformin "medical valley" 1000 mg filmovertrukne tabletter
medical valley invest ab - metforminhydrochlorid - filmovertrukne tabletter - 1000 mg
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).